Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Rough

Cardiovascular Disease National City, CA Medical Doctor

NPI 1386821460 CMS profile 153248

502 Euclid Ave, Ste 104, National City, CA 91950

Open in the dashboard

General payments

$18,956

687 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Rough of National City, CA is reported in the CMS Open Payments database as having received $18,956 across 687 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,757 112
2024 General $1,491 59
2023 General $1,501 56
2022 General $2,348 91
2021 General $1,846 94
2020 General $1,389 67
2019 General $4,624 208

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Rough
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Steven Rough were reported at $5,757. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Steven Rough Cardiovascular Disease median Middle half National median
2019 $4,624 $450 $127–$1,392 $163
2020 $1,389 $242 $77–$751 $114
2021 $1,846 $335 $101–$1,037 $132
2022 $2,348 $395 $121–$1,211 $149
2023 $1,501 $443 $136–$1,283 $160
2024 $1,491 $450 $136–$1,323 $164
2025 $5,757 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $5,051 64 payments
  2. Novartis Pharmaceuticals Corporation $1,398 85 payments
  3. Medtronic, Inc. $1,355 45 payments
  4. Medtronic Vascular, Inc. $949 27 payments
  5. Biotronik Inc. $849 24 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $795 44 payments
  7. Boston Scientific Corporation $581 30 payments
  8. Abbott Laboratories $561 23 payments
  9. Abiomed $470 8 payments
  10. Merck Sharp & Dohme Corporation $446 20 payments
  11. Other $6,502 317 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,252 671 payments
  2. Travel and Lodging $2,370 7 payments
  3. Education $335 9 payments
Products named General payments · program years 2019–2025
  1. SAPIEN 3 Ultra RESILIA $3,177 39 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $1,154 23 payments
  3. Micra Pacemakers $924 30 payments
  4. LifeVest $795 44 payments
  5. ENTRESTO $748 49 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $697 1 payment
  7. VERQUVO $522 23 payments
  8. MICRA Pacemakers $404 5 payments
  9. ELIQUIS $383 23 payments
  10. XARELTO $371 32 payments
  11. Other $10,414 474 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,168

Median for Interventional Cardiology: 2,236

Drug cost

$646,918

Median for Interventional Cardiology: $380,412

Branded share of claims

35.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 229 $270,583
Entresto Sacubitril/Valsartan Brand 155 $225,426
Jardiance Empagliflozin Brand 58 $77,266
Brilinta Ticagrelor Brand 40 $37,998
Farxiga Dapagliflozin Propanediol Brand 15 $8,173
Ranolazine Er Ranolazine Brand 32 $4,293
Atorvastatin Calcium Generic 188 $2,654
Metoprolol Succinate Generic 203 $2,312
Clopidogrel Clopidogrel Bisulfate Brand 96 $1,943
Diltiazem 12hr Er Diltiazem Hcl Brand 19 $1,705

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$295,601

Of which drugs: $1,262

Medicare patients

426

Average age 77

Services billed

3,628

229 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 54%
Ischemic heart disease 52%
Arthritis 46%
Chronic kidney disease 44%
Heart failure 38%
Atrial fibrillation 37%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 56 224 $1,262

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $141
$141 155 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $132
$132 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $105
$105 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $87
$87 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

687 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record